- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Include diagnostic criteria for Postherpetic neuralgia, neuropathic Pain: CDSCO panel tells Sun Pharma on Gabapentin study
New Delhi: Citing that specific diagnostic criteria for Postherpetic neuralgia (PHN) and neuropathic pain as per international guidelines should be included in the study protocol, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major Sun Pharma's proposal to conduct the Phase IV clinical trial of Gabapentin extended released (ER) Tablets 300mg and 600mg.
In addition, the expert panel stated that psychological problems/disorders of patients should be mentioned in the exclusion criteria.
This came after Sun Pharma presented a proposal for a grant of permission to conduct a Phase IV clinical trial of Gabapentin ER Tablets 300mg and 600mg along with a Phase IV clinical trial protocol before the committee.
Gabapentin is in a class of medications called anticonvulsants. Gabapentin treats seizures by decreasing abnormal excitement in the brain. Gabapentin relieves the pain of PHN by changing the way the body senses pain. It is not known exactly how gabapentin works to treat restless legs syndrome.
Gabapentin is used to treat epilepsy. It's also taken for nerve pain, which different conditions, including diabetes and shingles, can cause. Nerve pain can also happen after an injury. In epilepsy, it's thought that gabapentin stops seizures by reducing the abnormal electrical activity in the brain.
Gabapentin modulates the action of the GABA synthetic enzyme, glutamic acid decarboxylase (GAD), and the glutamate-synthesizing enzyme, branched-chain amino acid transaminase. Results with human and rat brain NMR spectroscopy indicate that gabapentin increases GABA synthesis.
At the recent SEC meeting for Neurology and Psychology held on 12th October 2023, the expert panel reviewed the proposal presented by the drug major Sun Pharma for a grant of permission to conduct a Phase IV clinical trial of Gabapentin ER Tablets 300mg and 600mg.
After detailed deliberation, the Committee recommended the grant of permission to conduct the Phase IV clinical trial study as per the protocol presented by the firm subject to the following conditions:
1. Specific diagnostic criteria for PHN and neuropathic pain as per international guidelines should be included in the study protocol.
2. Psychological problem/disorder patients should be mentioned in the exclusion criteria.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.